Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

The votes in favor of Merck's shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom are well-known vaccine critics.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

A group of outside advisers to the US Centers for Disease Control and Prevention voted 5-2 to recommend use of a new shot that can protect babies from respiratory syncytial virus, adding an additional ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity medicines, bringing cheap active ingredients from China often labeled as for ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

Kennedy’s controversial panel overhaul met its first test. The result? A major win for public health ahead of RSV season.

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials.